OMNIGEN BIOTECHNOLOGICAL APPLICATIONS S.A.
OMNIGEN BIOTECHNOLOGICAL APPLICATIONS S.A. is the leading biotechnology company in Greece, founded in 2006. Specializing in stem cell storage, cell therapies, and regenerative medicine, the company has positioned itself as one of the most modern, integrated, and innovative laboratories in Europe. With a focus on novel technologies and a highly trained workforce, OMNIGEN initially established its presence as a leading umbilical cord stem cell bank. Expanding its scope, the company ventured into regenerative medicine using autologous adult stem cells and growth factors, forging collaborations with major medical institutions in Greece and abroad. Notably, OMNIGEN is the first company in Greece with experience in autologous hepatopoietic stem cell transplantation and vast expertise in autologous transplantation of adipose-derived stem cells, application of autologous growth factors in various medical fields including plastic surgery, reconstructive medicine, and tissue repair. Moreover, the company has extended its business to diverse areas such as Aesthetic Medicine, Orthopaedics, Arthroplastic Surgery, Sports Medicine, Dentistry, Ulcer treatment, and Ophthalmology.
There is no investment information
No recent news or press coverage available for OMNIGEN BIOTECHNOLOGICAL APPLICATIONS S.A..